Amubarvimab + Romlusevimab (BRII-196/BRII-198)
COVID-19
Key Facts
About Brii Biosciences
Founded in 2018, Brii Biosciences is a publicly traded biotech with a mission to address major public health challenges in infectious diseases and CNS disorders. Its core strategy involves in-licensing and co-developing clinical-stage assets, most notably achieving the first NMPA-approved COVID-19 neutralizing antibody combination in China. The company operates with a dual-US/China footprint, aiming to accelerate global innovation for patients in high-need markets.
View full company profileTherapeutic Areas
Other COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| PanCytoVir™ (oral probenecid) | TrippBio | Phase 2 |
| ARCoV | Abogen | Approved (EUA) |
| OT-101 | Sapu BioScience | Clinical Trial (Phase not specified) |
| COVID-19 Vaccine (Inactivated) | Kangtai Biological Products | Approved |
| COVID-19 Vaccine (Adenovirus Vector) | Kangtai Biological Products | Approved |
| Idylla SARS-CoV-2 Test | Biocartis | Approved |
| Adjuvanted Cell-Based COVID-19 Vaccine | CSL Seqirus | Marketed |
| Sequential Dialysis Technique | Halberd | Discovery |
| COVID-19 Vaccine Testing (for AstraZeneca) | Advaxia Biologics | Approved |
| COVID-19 Vaccine Clinical Batches | Advaxia Biologics | Clinical |
| UOL COVID-19 Test | Uh-Oh Labs | Approved |